Literature DB >> 17351389

Src, chemoresistance and epithelial to mesenchymal transition: are they related?

Ami N Shah1, Gary E Gallick.   

Abstract

The Src family of nonreceptor tyrosine kinases regulates numerous cellular processes, including proliferation, differentiation, migration, survival and angiogenesis. In solid tumors, Src is frequently aberrantly active, and promotes tumor progression and metastasis. Although multiple Src functions may contribute to metastasis, recently Src has been shown to play a role in epithelial to mesenchymal transition. Increased Src activity promotes this process and inhibition of Src suppresses epithelial to mesenchymal transition. Although the molecular events causing epithelial to mesenchymal transition are becoming well defined, the processes in tumor cells that trigger the onset of this phenotype remain unclear. Recent studies have associated epithelial to mesenchymal transition with the development of chemoresistance. Src has also been shown to be involved in chemoresistance of cancer cells. The activation of Src in chemoresistant cells is related to an increase in motility, invasiveness and detachment, all phenotypes characteristic both of Src activation and of epithelial to mesenchymal transition. This review focuses on upregulation of Src in cancer as it relates to chemoresistance and epithelial to mesenchymal transition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351389     DOI: 10.1097/CAD.0b013e32801265d7

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  23 in total

Review 1.  Involvement of members of the cadherin superfamily in cancer.

Authors:  Geert Berx; Frans van Roy
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09-23       Impact factor: 10.005

2.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

3.  Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.

Authors:  Zhiyong Du; Renyi Qin; Cuifeng Wei; Min Wang; Chengjian Shi; Rui Tian; Chenghong Peng
Journal:  Dig Dis Sci       Date:  2010-08-04       Impact factor: 3.199

4.  Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance.

Authors:  Yann Wallez; Stefan J Riedl; Elena B Pasquale
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

5.  NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer.

Authors:  Yann Wallez; Peter D Mace; Elena B Pasquale; Stefan J Riedl
Journal:  Genes Cancer       Date:  2012-05

6.  SRC points the way to biomarkers and chemotherapeutic targets.

Authors:  Harini Krishnan; W Todd Miller; Gary S Goldberg
Journal:  Genes Cancer       Date:  2012-05

7.  Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.

Authors:  Bart M Maślikowski; Benjamin D Néel; Ying Wu; Lizhen Wang; Natalie A Rodrigues; Germain Gillet; Pierre-André Bédard
Journal:  BMC Cancer       Date:  2010-02-12       Impact factor: 4.430

8.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

Authors:  Victoria Bolós; Joan Manuel Gasent; Sara López-Tarruella; Enrique Grande
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

9.  BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling.

Authors:  Natasha R Schuh; Michael S Guerrero; Randy S Schrecengost; Amy H Bouton
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

10.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.

Authors:  Martin Michaelis; Denise Klassert; Susanne Barth; Tatyana Suhan; Rainer Breitling; Bernd Mayer; Nora Hinsch; Hans W Doerr; Jaroslav Cinatl; Jindrich Cinatl
Journal:  Mol Cancer       Date:  2009-09-29       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.